Search company, investor...
NanoTechnology Solutions company logo

NanoTechnology Solutions

Founded Year


About NanoTechnology Solutions

NanoTechnology Solutions offers solutions for nanotechnology applications. The company offers products including electron microscopy, 3D profilometry, microscopy sample preparation, vibration isolation, electrospinners, and more. It was founded in 2015 and is based in Adelaide, Australia.

Headquarters Location

91 King William St Level 30, Westpac House

Adelaide, South Australia, 5000,


Missing: NanoTechnology Solutions's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NanoTechnology Solutions's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

NanoTechnology Solutions Frequently Asked Questions (FAQ)

  • When was NanoTechnology Solutions founded?

    NanoTechnology Solutions was founded in 2015.

  • Where is NanoTechnology Solutions's headquarters?

    NanoTechnology Solutions's headquarters is located at 91 King William St, Adelaide.

  • Who are NanoTechnology Solutions's competitors?

    Competitors of NanoTechnology Solutions include Grundium and 4 more.

Compare NanoTechnology Solutions to Competitors

PreciPoint Logo

PreciPoint manufactures solutions for the digitization of microscopy and laboratory processes for applications in medicine, research, and teaching. Its offerings include digital microscopes & scanners, services, and microscopy software. The company was founded in 2018 and is based in Freising, Germany.


MediSpectra, Inc. is a medical device company developing optical detection technology for enhanced accuracy and real-time results in the detection of cancer and other human tissue abnormalities. The technology is based on multimodal optical interrogation of tissue with light. Specifically, a combination of native fluorescence and white light backscatter spectroscopies are coupled with video imaging methods to more accurately detect tissue abnormalities. nnThe company's first product, the LUMA Cervical Imaging System, was designed and developed to improve the detection of high-grade pre-cancerous cervical abnormalities that have the potential of becoming invasive cancer. The LUMA product is intended for use as an adjunct to colposcopy in identifying high grade disease (CIN 2/3+) in patients referred to colposcopy with an ASCUS, LSIL or HSIL+ cervical cytology test result. n

Stage I Diagnostics Logo
Stage I Diagnostics

Stage I Diagnostics is a cancer biotechnology company focused on providing early stage diagnosis provided by new biomarkers deployed through In-Vitro Diagnostics (IVD). The company's initial focus is the early diagnosis of ovarian cancer. Stage I's core competency is the process of converting newly discovered genes into commercial products which impact clinical decisions. The company's approach is to determine what characteristics new biomarkers should have to achieve the best diagnostic results in targeted diseases and then to discover what genes exist that fit those characteristics. This process has led us to not only discover and patent numerous genes associated with various types of cancer but also clone 4 new genes.


Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

Microwave Imaging System Technologies (MIST)

Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.

Spectral Image

a privately held, early stage medical device company focused on the development of imaging technology for biomedical use. The company is currently in stealth-mode and not disclosing the finer details of its technology until it secures necessary intellectual property rights. Spectral Image will initiate a pilot study of its technology at a premier medical facilities in 2008.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.